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Abstract
Background
ADHD is the most common neuropsychiatric condition affecting individuals of
all ages. Long-term outcomes of affected individuals and association with severe
comorbidities as SUD or conduct disorders are the main concern. Genetic asso-
ciations have been extensively described. Multiple studies show that intronic
variants harbored in the ADGRL3 (LPHN3) gene are associated with ADHD,
especially associated with poor outcomes.
Methods
In this study, we evaluated this association in the Multimodal Treatment Study
of children with ADHD (MTA), initiated as a 14-month randomized clinical
trial of 579 children diagnosed with DSM-IV ADHD-Combined Type (ADHD-
C), that transitioned to a 16-year prospective observational follow-up, and 289
classmates added at the 2-year assessment to serve as a local normative compar-
ison group (LNCG). Diagnostic evaluations at entry were based on the Diag-
nostic Interview Schedule for Children-Parent (DISC-P), which was repeated at
several points over the years. For an add-on genetic study, blood samples were
collected from 232 in the MTA group and 139 in the LNCG.
Results
For the 205 MTA participants, 14.6% retained the DISC-P diagnosis of ADHD-
C in adolescence. For 127 LNCG participants, 88.2% remained undiagnosed by
the DISC-P. We genotyped 15 polymorphic SNP markers harbored in the
ADGRL3 gene, and compared allele frequencies for the 30 cases with continued
diagnosis of ADHD-C in adolescence to the other participants. Replication of
the association of rs2345039 ADGRL3 variant was observed (P value = 0.004,
FDR corrected = 0.03; Odds ratio = 2.25, upper CI 1.28–3.97).
Conclusion
The detection of susceptibility conferred by ADGRL3 variants in the extreme
phenotype of continued diagnosis of ADHD-C from childhood to adolescence
provides additional support that the association of ADGRL3 and ADHD is not
spurious. Exploring genetic effects in longitudinal cohorts, in which refined,
age-dependent phenotypes are documented, is crucial to understand the natural
history of ADHD.
ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
1
Introduction
Family, twin, and case–control-based linkage and associa-
tion studies indicate that genetics play a crucial role in
shaping susceptibility to both ADHD and disruptive
behaviors (Arcos-Burgos et al. 2012; Jain et al. 2012).
Using genome wide data, we found evidence of linkage of
ADHD to chromosomes 4q13.2, 5q33.3, 8q11.23, 11q22,
and 17p11 (Arcos-Burgos et al. 2004). Furthermore,
linkage and association analyses revealed not only coseg-
regation between ADHD and disruptive behaviors but
also the existence of common signals of linkage to several
loci (Jain et al. 2007). Reverse genetics allowed us to
identify variants in the adhesion G-protein-coupled receptor
L3 gene (ADGRL3, also known as latrophilin 3 or LPHN3)
(Accession number NC_000004.12, GRCh38.p2)
(OMIM:616417) at 4q13.2 that predisposes to ADHD and
disruptive behaviors (Arcos-Burgos et al. 2010; Acosta
et al. 2011; Domene et al. 2011; Martinez et al. 2011;
Ribases et al. 2011; Jain et al. 2012). Using cohorts of
thousands of individuals from Colombia, Germany, Nor-
way, Spain, and the United States, we found a significant
homogeneous genetic effect of ADGRL3 variants predis-
posing to ADHD in children, adolescents, and adults, and
predicting the response to stimulant medication, (Arcos-
Burgos et al. 2010, 2012; Ribases et al. 2011; Fallgatter
et al. 2013). These results were independently replicated
in four additional pharmacogenetic studies from Canada,
Brazil, and Korea (Choudhry et al. 2012; Labbe et al.
2012; Bruxel et al. 2015; Hwang et al. 2015).
ADGRL3 is a member of the latrophilin subfamily of
G-protein-coupled receptors (GPCRs) (Martinez et al.
2011). Latrophilin ADGRL1 and ADGRL2 serve as recep-
tors for alpha-latrotoxin, a component of the venom of
the black widow spider (Latrodectus mactans) (Martinez
et al. 2011). We showed that ADGRL3 is only expressed
almost exclusively in the brain and mostly is highly
expressed in regions neurophysiologically associated with
the pathology of ADHD (Arcos-Burgos et al. 2010).
Recently, the identification of the fibronectin family of
leucine-rich repeat transmembrane protein 3 (FLRT3)
was identified as an endogenous postsynaptic ligands for
ADGRL3, facilitated the identification of a high-affinity
trans interaction between the ADGRL3 ectodomain with
its ligand, FLRT3 (O’Sullivan et al. 2012) and interfering
with this interaction reduces excitatory synapse density in
cultured neurons and decreases afferent input strength
and dendritic spine number in dentate granule cells. This
suggests that the ADGRL3 and its ligand- FLRT3 partner-
ship plays an important role in glutamatergic synapse
development (O’Sullivan et al. 2012). We found that gene
ontology pathways involved in axon guidance, regulation
of synaptic transmission, and regulation of transmission
of nerve impulse, are overrepresented when ADGRL3
variants associated with ADHD are tested. In agreement
with our results, data from a mutant knockout mouse
model null for the Adgrl3, gene as well as the loss of
function of the ortholog adgrl3.1 during zebrafish devel-
opment, also support the implication of ADGRL3 in
ADHD pathophysiology (Arcos-Burgos et al. 2012; Lange
et al. 2012; Wallis et al. 2012).
In this study, we explored the association of ADGRL3
variants with ADHD in the Multimodal Treatment Study
of children with ADHD (MTA). The MTA study was ini-
tiated as a 14-month randomized clinical trial of 579 chil-
dren diagnosed with DSM-IV ADHD-Combined Type
(ADHD-C, between 7.0 and 9.9 years of age) that transi-
tioned to a 16-year prospective observational follow-up,
and 289 classmates added at the 2-year assessment to
serve as a local normative comparison group (LNCG).
Outcomes at the end of the randomized clinical trial and
at follow-up in childhood and adolescence have been
reported (1999; Jensen et al. 2007; Molina et al. 2013,
2009; Molina and Pelham 2003). Exploring genetic associ-
ation in longitudinal studies, in which age-dependent
refined phenotypes are ascertained prospectively, is crucial
to better understand genetic effects on the natural history
of ADHD (Faraone et al. 2006; Franke et al. 2012).
Material and Methods
Ethical complience
The MTA study is a cooperative treatment study per-
formed by six independent research teams in collabora-
tion with the Division of Services and Intervention
Research, National Institute of Mental Health, and the
Office of Special Education Programs, U.S. Department of
Education, Washington, DC (The MTA Cooperative
Group 1999). Research was conducted in accordance with
the ethical guidelines of both local institutional review
boards and the National Institutes of Health Office for
Protection From Research Risks, Bethesda, MD.
Subjects
The MTA was designed to evaluate long-term effects of
treatments for ADHD in a 14-month randomized con-
trolled trial of 579 children assigned to a four treatment
groups – medication management, behavior modification,
their combination, and treatment as usual in community
care. After the 14-month treatment-by-protocol phase,
the MTA continued as a naturalistic follow-up, in which
self-selected use of psychoactive medication was moni-
tored. A LNCG of 289 randomly selected classmates
group-matched for grade and sex was added when the
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ADHD participants were between 9 and 12 years of age.
The outcomes in childhood (14, 24, 36 months after
baseline), and adolescence (6 and 8 years after baseline)
have been reported (1999; Jensen et al. 2007; Molina
et al. 2013, 2009; Molina and Pelham 2003). In the MTA,
the participants were diagnosed in childhood based on
the DSM-IV criteria for ADHD subtypes (hyperactive/im-
pulsive, inattentive, and combined) using the Diagnostic
Interview Schedule for Children-Parent Version (DISC-
P), supplemented with teacher report of symptoms. The
DISC-P was administered at entry (in childhood) and at
each of the prospective follow-up assessments, including
the 6-year follow-up when the participants were between
13.0 and 15.9 years of age in thus in adolescence.
Clinical observations and longitudinal studies document
that symptom presence and severity decrease over time in
some children with ADHD, resulting in decreased diagno-
sis with age (Faraone et al. 2006; Franke et al. 2012). In the
prospective follow-up of the MTA, a refined phenotype
based on DSM-IV diagnostic persistence was established by
determining the cases that maintained the parent-reported
symptoms of the disorder in adolescence (persistent
ADHD-C). We used this refined phenotype to study the
association of the ADGRL3 genetic variants with ADHD.
We hypothesized that those with persistence of the symp-
toms that qualified them for entry into the study as chil-
dren would be more likely as adolescents to have ADGRL3
genetic susceptibility compared to those whose diagnostic
subtype shifted or disappeared. This highly vulnerable sub-
group may also be more susceptible to poor outcomes as
described elsewhere (Arcos-Burgos et al. 2010).
Genotyping
Genomic DNA was extracted from whole blood using the
QIAamp DNA Blood Maxi Kit (QIAGEN, Germantown,
MD). Samples were subjected to whole-exome genotyping
using the Illumina HumanExome BeadChip-12v1_A,
which covers putative functional exonic variants selected
from over 12,000 individuals. The exonic content consists
of >250,000 markers representing diverse populations –
including European, African, Chinese, and Hispanic indi-
viduals – and a range of common conditions, such as
type 2 diabetes, cancer, metabolic, and psychiatric disor-
ders. Four open controls per 96-well-plate were used for
internal quality control, including two positive and two
blank controls. Duplicates assessed data quality across all
plates. Genotyping from nonmatching duplicates was
dropped. Only data generated by SNP assays that were
successfully genotyped on at least 90% of samples were
analyzed. In addition, we genotyped the ADGRL3 (Acces-
sion number NC_000004.12, GRCh38.p2) susceptibility
haplotype variants rs2345039, rs6551665, and rs1947274
previously reported (Arcos-Burgos et al. 2010), which
were not represented in the exome chip. Briefly, genotyp-
ing was performed using TaqMan SNP Genotyping
Assays (Thermo Fisher Scientific, Grand Island, NY). Alle-
lic discrimination real-time PCR reactions were per-
formed in a 384-well-plate format in duplicate for each
individual sample according to manufacturer’s instruc-
tions. Briefly, 20 ng of genomic DNA was mixed with
2.5 lL of 29 TaqMan Universal PCR Master Mix and
0.25 lL of 209 SNP Genotyping Assay in a total volume
of 5 lL per well. Assays were run in an ABI 7900HT Fast
Real-Time PCR System (Thermo Fisher Scientific, Grand
Island, NY). Allele calling was determined by end-point
fluorescent signal analysis using the ABI’s SDS2.3
software (SABiosciences - QIAGEN Inc., 27220, Turnberry
Lane, Valencia, CA 91355).
Quality control and filtering
GenomeStudio data were imported to SVS 7.6.7, Golden
Helix’s (Golden Helix, Inc. Bozeman, MT (http://www.-
goldenhelix.com), an integrated collection of analytic tools
for managing, analyzing, and visualizing multifaceted
genomic and phenotypic data. Parameters for excluding
markers from analyses included: (1) deviations from the
Hardy–Weinberg equilibrium with P < 0.0000002 (0.05/
250.000 markers) in both cases and controls, (2) a geno-
type call rate <90%, and (3) the presence of both more or
less than two alleles. Genotype and allelic frequencies were
estimated by maximum likelihood. Data subsets for com-
mon and rare variants where established using a minor
allele frequency (MAF) criterion of 1.0% that was esti-
mated from the whole sample data. Linkage disequilibrium
(LD) pruning using CHM was applied to the subset of
common markers using as parameters a window size of 50
markers with a window increment of 50 and an r2 thresh-
old of 0.5. With this pruned subset of common markers,
matrices of identity by descent (IBD) and probability of
identity were estimated. Those were used afterward for the
mixed models analyses.
Genetic analysis
Single allelic, additive, and dominant linear-mixed effect
models (LMEMs) (Liu and Leal 2010a,b; Segura et al.
2012) were fitted to test the association of these variants to
ADHD. The advantage of these models is the inclusion of
both fixed (sex and years of education, among other clini-
cal variables) and random effects (the later to account for
kinship effects by including the IBD matrix). The single-
locus LMEM assumes that all loci have a small effect on the
trait, while multi-locus LMEM assume that several loci
have a large effect on the trait. In a single-locus model, the
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association between the variant of interest and the disease
trait is tested after covariates and genetic stratification are
controlled for. Conversely, in a multi-locus model the asso-
ciation is tested after covariates, genetic stratification and
the effect of the remaining m-1 variants are controlled for.
These recently emerged methods have been proven to be
more powerful than existing methods (Segura et al. 2012).
Furthermore, this family of models allows handling of con-
founding effects and account for loci of small- and large-
effect in structured populations with a small computational
burden (Segura et al. 2012). Variants significantly associ-
ated with the ADHD phenotype were determined after cor-
rection by multiple testing using the false discovery rate
(FDR) (Benjamini and Hochberg 1995) and an alternative
method based on extreme-values theory (Velez et al. 2014).
As this is an attempt of evaluate an already known associa-
tion, we have used the criterion of a P-value ≤0.10 to con-
sider a positive replication.
Results
A full description of demographic and clinical variables of
the MTA has been published elsewhere (1999; Jensen
et al. 2007; Molina et al. 2013, 2009; Molina and Pelham
2003). For a genetic add-on we genotyped 371 volunteers
(280 males, 75%), consisting of 232/579 = 40.0% of the
MTA group and 139/289 = 48.1% of the LNCG. Diag-
noses from the 6-year DISC-P were available for 205 of
the MTA and 127 of the LNCG volunteers. For the 205
MTA participants in the genetic add-on study, 30/205
(14.6%) retained the DISC-P diagnosis of ADHD-C in
adolescence, but 175/205 (85.4%) did not, with switches
in adolescence to ADHD-Inattentive Type (ADHD-I) for
59/205 (28.8%), ADHD-Hyperactive Type (ADHD-HI)
for 8/205 = 3.9%, and no subtype of ADHD for 108/205
(52.7%). For the 127 LNCG participants in the genetic
add-on study, 112/127 (88.2%) remained undiagnosed in
adolescence by the DISC-P, but 15/127 (11.8%) did not,
and all of these 15 were diagnosed with Adolescent
ADHD-I (see Fig. 1 and Table 1).
Using LMEMs we initially compared allelic, genotype,
and haplotype data of MTA and LNCG at the base line
diagnosis but found no significant differences. For the
subgroup with persisting combined type ADHD, we
found significant associations with ADGRL3 for allelic
and haplotype comparisons, when compared with the
other adolescent subgroups (adolescent ADHD-I, ADHD-
HI, or Non-ADHD). The minor allele C at the marker
579 289 
MTA LNCG 
Initial Sample 
371 
Genotype NIH 
Genotype 
232 139 
MTA LNCG 
(27 without 6-yr (12 without 6-yr 
DISC = 205) DISC = 117) 
Phenotype in Adolescence 
(At 6-year Assessment) 
30 continued ADHD Combined 
175 no longer ADHD Combined 
108 Desistent ADHD-C 
8 became ADHD-HI 
59 became ADHD-I 
112 Continued Non-ADHD 
15 no longer Non-ADHD 
0 emergent ADHD-C 
0 emergent ADHD-HI 
15 emergent ADHD-I 
Figure 1. Diagram of individuals participation
in the studies and collected DNA samples in
relation of ADHD diagnosis.
4 ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
ADHD Susceptibility and ADGRL3 Biomarkers M. T. Acosta et al.
rs2345039 was significant (P = 0.005) after corrections by
multiple comparisons (PFDR = 0.04), which is the same
marker reported to be significant in the original manu-
script that described variants harbored in ADGRL3confer-
ring susceptibility to ADHD by our group (Arcos-Burgos
et al. 2010). The haplotype analysis show that a haplotype
involving rs2345039-rs61747658-rs1397548 (CAA) is sig-
nificantly associated with a refined phenotype of adoles-
cent-persistent ADHD-C when compared with the LNCG
(P = 0.005, PFDR = 0.05; Odds ratio = 3.47, CI-95%
1.37–8.74 (Table 2). This significant association, based on
a comparison of the n = 30 cases with persistent ADHD-
C versus the LNCG, was independent of the fitted model,
that is, allelic, genotype dominant, or genotype codomi-
nant, and in each case the association tolerated FDR cor-
rection (Table 3). We also compared the subgroup with
persisting ADHD-C with the subgroup consisting of the
other subtypes representing partial manifestation of the
full syndrome (ADHD-I and ADHD-HI), but we found
no differences.
Discussion
A large number of studies show that ADGRL3 variants
predispose to ADHD, modulate the pattern of brain
metabolism, and predict ADHD severity (comorbidity
with conduct disorder [CD], oppositional defiant disorder
[ODD], and substance used disorder [SUD]) and
response to stimulant medication (Arcos-Burgos and
Muenke 2010; Arcos-Burgos et al. 2010, 2012; Acosta
et al. 2011; Martinez et al. 2011; Ribases et al. 2011; Jain
et al. 2012). Furthermore, ADGRL3 susceptibility variants
interact with haplotype variants harbored at chromosome
11q22 in the region of NCAM1, TTC12, ANKK1, and
DRD2 genes (Jain et al. 2012). It is clear now that the
association between ADHD and ADGRL3 variants identi-
fies a subtype of the condition characterized by the pres-
ence of severe externalizing symptoms and consequently a
complex prognosis of persistence and graveness.
Table 1. Cross tabulation of ADHD combined type based on the
diagnostic interview schedule for children–parent version (DISC-P)
administered at the 6-year follow-up assessment (PAD3Y) versus the
diagnosis of ADHD at the baseline. The unknown category refers to
those cases without PAD3Y criteria. The 112 LNCG are those that did
not match ADHD criteria at the 6-year follow-up assessment, that is,
15 individuals.
SJTYP
PAD3Y PAD3Y PAD3Y Row
Control
ADHD
combined type Unknown Totals
MTA 175 30 27 232
LNCG 112 0 12 124
Totals 287 30 39 356
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In this manuscript, we present additional evidence that
the ADGRL3 variant rs2345039, previously reported to be
associated with the ADHD susceptibility haplotype, pre-
disposes to the development of a refined ADHD pheno-
type characterized by persistence of ADHD combined
subtype symptoms into adolescence. The fact that we are
detecting association of the ADGRL3 variants in an
extreme phenotype based on outcome of 6 years after
childhood diagnosis – and confirmed by a rigorous
prospective follow-up – provides additional evidence that
the association with ADGRL3 not only is not spurious,
but also is associated with a more severe form of ADHD.
These findings may partially explain the heterogeneity of
longitudinal course in ADHD that includes differential
symptom reduction with age, comorbidity, and ultimately,
overall long-term physical and mental health. Limitations
of this study include the use of a final small sample size for
those with persistent phenotype for ADHD at 6 years of
age. However, it is known that in small sample size cohorts,
where a high number of markers have been genotyped,
major fluctuations in the distribution of significant values
might appear and, consequently, spurious associations
might reach significance. To control for this problem, we
corrected by multiple comparisons using FDR as described
in the Methods section. Furthermore, given that the direc-
tion of association between ADHD susceptibility and
LPHN3 variants is well known, a P-value of 0.10 was
selected as the threshold to declare significance. The reason
for selecting this threshold lies in the demonstration that
for a given P-value, the probability of replicating a signifi-
cant result, under certain assumptions, is smaller than
expected. Or better, as described by Goodman (Goodman
1992): “It is shown that if the observed difference is the
true one, the probability of repeating a statistically signifi-
cant result, the “replication probability”, is substantially
lower than expected”.
Continued research on this genetic variant in samples
followed into adulthood, and that include comprehensive
assessment of symptoms and functioning, is warranted.
Conflict of Interest
The authors declare no conflict of interests.
References
Acosta, M. T., J. I. Velez, M. L. Bustamante, J. Z. Balog, M.
Arcos-Burgos, and M. Muenke. 2011. A two-locus genetic
interaction between LPHN3 and 11q predicts ADHD
severity and long-term outcome. Transl. Psychiatry 1:e17.
Arcos-Burgos, M., and M. Muenke. 2010. Toward a better
understanding of ADHD: LPHN3 gene variants and the
susceptibility to develop ADHD. Atten. Defic. Hyperact.
Disord. 2:139–147.
Arcos-Burgos, M., F. X. Castellanos, D. Pineda, F. Lopera, J.
D. Palacio, L. G. Palacio, et al. 2004. Attention-deficit/
hyperactivity disorder in a population isolate: linkage to loci
at 4q13.2, 5q33.3, 11q22, and 17p11. Am. J. Hum. Genet.
75:998–1014.
Arcos-Burgos, M., M. Jain, M. T. Acosta, S. Shively, H.
Stanescu, D. Wallis, et al. 2010. A common variant of the
latrophilin 3 gene, LPHN3, confers susceptibility to ADHD
and predicts effectiveness of stimulant medication. Mol.
Psychiatry 15:1053–1066.
Arcos-Burgos, M., J. I. Velez, B. D. Solomon, and M. Muenke.
2012. A common genetic network underlies substance use
disorders and disruptive or externalizing disorders. Hum.
Genet. 131:917–929.
Benjamini, Y., and Y. Hochberg. 1995. Controlling the false
discovery rate: a practical and powerful approach to
multiple testing. J. R. Stat. Soc. Series B Stat. Methodol.
57:289–300.
Bruxel, E. M., A. Salatino-Oliveira, G. C. Akutagava-Martins,
L. Tovo-Rodrigues, J. P. Genro, C. P. Zeni, et al. 2015.
LPHN3 and attention-deficit/hyperactivity disorder: a
susceptibility and pharmacogenetic study. Genes Brain
Behav. 14:419–427.
Choudhry, Z., S. M. Sengupta, N. Grizenko, M. E. Fortier, G.
A. Thakur, J. Bellingham, et al. 2012. LPHN3 and attention-
deficit/hyperactivity disorder: interaction with maternal
stress during pregnancy. J. Child Psychol. Psychiatry 53:892–
902.
Domene, S., H. Stanescu, D. Wallis, B. Tinloy, D. E. Pineda,
R. Kleta, et al. 2011. Screening of human LPHN3 for
variants with a potential impact on ADHD susceptibility.
Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B:11–18.
Fallgatter, A. J., A. C. Ehlis, T. Dresler, A. Reif, C. P. Jacob, M.
Arcos-Burgos, et al. 2013. Influence of a Latrophilin 3
(LPHN3) risk haplotype on event-related potential measures
of cognitive response control in attention-deficit
hyperactivity disorder (ADHD). Eur.
Neuropsychopharmacol. 23:458–468.
Faraone, S. V., J. Biederman, T. Spencer, E. Mick, K. Murray, C.
Petty, et al. 2006. Diagnosing adult attention deficit
hyperactivity disorder: are late onset and subthreshold
diagnoses valid? Am. J. Psychiatry, 163:1720–1729; quiz 1859.
Franke, B., S. V. Faraone, P. Asherson, J. Buitelaar, C. H. Bau,
J. A. Ramos-Quiroga, et al. 2012. The genetics of attention
deficit/hyperactivity disorder in adults, a review. Mol.
Psychiatry 17:960–987.
Goodman, S. N. 1992. A comment on replication, p-values
and evidence. Stat. Med. 11:875–879.
Hwang, I. W., M. H. Lim, H. J. Kwon, and H. J. Jin. 2015.
Association of LPHN3 rs6551665 A/G polymorphism with
attention deficit and hyperactivity disorder in Korean
children. Gene 566:68–73.
Jain, M., L. G. Palacio, F. X. Castellanos, J. D. Palacio, D.
Pineda, M. I. Restrepo, et al. 2007. Attention-deficit/
7ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
M. T. Acosta et al. ADHD Susceptibility and ADGRL3 Biomarkers
hyperactivity disorder and comorbid disruptive behavior
disorders: evidence of pleiotropy and new susceptibility loci.
Biol. Psychiatry 61:1329–1339.
Jain, M., J. I. Velez, M. T. Acosta, L. G. Palacio, J. Balog, E.
Roessler, et al. 2012. A cooperative interaction between
LPHN3 and 11q doubles the risk for ADHD. Mol.
Psychiatry 17:741–747.
Jensen, P. S., L. E. Arnold, J. M. Swanson, B. Vitiello, H. B.
Abikoff, L. L. Greenhill, et al. 2007. 3-year follow-up of the
NIMH MTA study. J. Am. Acad. Child Adolesc. Psychiatry
46:989–1002.
Labbe, A., A. Liu, J. Atherton, N. Gizenko, M. E. Fortier, S. M.
Sengupta, et al. 2012. Refining psychiatric phenotypes for
response to treatment: contribution of LPHN3 in ADHD.
Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B:776–785.
Lange, M., W. Norton, M. Coolen, M. Chaminade, S. Merker,
F. Proft, et al. 2012. The ADHD-susceptibility gene lphn3.1
modulates dopaminergic neuron formation and locomotor
activity during zebrafish development. Mol. Psychiatry
17:946–954.
Liu, D. J., and S. M. Leal. 2010a. A novel adaptive method for
the analysis of next-generation sequencing data to detect
complex trait associations with rare variants due to gene
main effects and interactions. PLoS Genet. 6:e1001156.
Liu, D. J., and S. M. Leal. 2010b. Replication strategies for rare
variant complex trait association studies via next-generation
sequencing. Am. J. Hum. Genet. 87:790–801.
Martinez, A. F., M. Muenke, and M. Arcos-Burgos. 2011.
From the black widow spider to human behavior:
latrophilins, a relatively unknown class of G protein-coupled
receptors, are implicated in psychiatric disorders. Am. J.
Med. Genet. B Neuropsychiatr. Genet. 156B:1–10.
Molina, B. S., and W. E. Jr Pelham. 2003. Childhood
predictors of adolescent substance use in a longitudinal
study of children with ADHD. J. Abnorm. Psychol.
112:497–507.
Molina, B. S., S. P. Hinshaw, J. M. Swanson, L. E. Arnold, B.
Vitiello, P. S. Jensen, et al. 2009. The MTA at 8 years:
prospective follow-up of children treated for combined-type
ADHD in a multisite study. J. Am. Acad. Child Adolesc.
Psychiatry 48:484–500.
Molina, B. S., S. P. Hinshaw, L. Eugene Arnold, J. M.
Swanson, W. E. Pelham, L. Hechtman, et al. 2013.
Adolescent substance use in the multimodal treatment study
of attention-deficit/hyperactivity disorder (ADHD) (MTA)
as a function of childhood ADHD, random assignment to
childhood treatments, and subsequent medication. J. Am.
Acad. Child Adolesc. Psychiatry 52:250–263.
O’Sullivan, M. L., J. de Wit, J. N. Savas, D. Comoletti, S.
Otto-Hitt, J. R. 3rd Yates, et al. 2012. FLRT proteins are
endogenous latrophilin ligands and regulate excitatory
synapse development. Neuron 73:903–910.
Ribases, M., J. A. Ramos-Quiroga, C. Sanchez-Mora, R. Bosch,
V. Richarte, G. Palomar, et al. 2011. Contribution of
LPHN3 to the genetic susceptibility to ADHD in adulthood:
a replication study. Genes Brain Behav. 10:149–157.
Segura, V., B. J. Vilhjalmsson, A. Platt, A. Korte, U. Seren, Q.
Long, et al. 2012. An efficient multi-locus mixed-model
approach for genome-wide association studies in structured
populations. Nat. Genet. 44:825–830.
The MTA Cooperative Group. 1999. A 14-month randomized
clinical trial of treatment strategies for attention-deficit/
hyperactivity disorder. The MTA Cooperative Group.
Multimodal Treatment Study of Children with ADHD.
Arch. Gen. Psychiatry 56:1073–1086.
Velez, J. I., J. C. Correa, and M. Arcos-Burgos. 2014. A new
method for detecting significant p-values with applications
to genetic data. Rev. Colomb. Estadist. 37:67–76.
Wallis, D., D. S. Hill, I. A. Mendez, L. C. Abbott, R. H.
Finnell, P. J. Wellman, et al. 2012. Initial characterization of
mice null for Lphn3, a gene implicated in ADHD and
addiction. Brain Res. 1463:85–92.
8 ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
ADHD Susceptibility and ADGRL3 Biomarkers M. T. Acosta et al.
